ICU Medical (NASDAQ:ICUI) Director George A. Lopez sold 7,640 shares of ICU Medical stock in a transaction on Wednesday, March 21st. The stock was sold at an average price of $253.83, for a total transaction of $1,939,261.20. Following the completion of the sale, the director now owns 526,574 shares of the company’s stock, valued at approximately $133,660,278.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of ICU Medical stock traded down $2.65 during trading hours on Thursday, hitting $249.95. 40,526 shares of the company were exchanged, compared to its average volume of 136,591. The company has a market capitalization of $5,118.56, a price-to-earnings ratio of 75.71, a PEG ratio of 2.55 and a beta of 0.42. ICU Medical has a fifty-two week low of $144.25 and a fifty-two week high of $265.27.
ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Thursday, March 1st. The medical instruments supplier reported $2.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.04 by $1.94. The business had revenue of $370.12 million during the quarter, compared to analyst estimates of $332.91 million. ICU Medical had a net margin of 5.31% and a return on equity of 8.42%. The business’s revenue was up 286.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.20 earnings per share. equities analysts predict that ICU Medical will post 6.29 earnings per share for the current year.
A number of brokerages recently issued reports on ICUI. BidaskClub upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Wednesday, March 7th. Zacks Investment Research upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $266.00 price target for the company in a research note on Tuesday, January 23rd. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. ICU Medical currently has a consensus rating of “Buy” and an average target price of $266.00.
ILLEGAL ACTIVITY WARNING: “ICU Medical (ICUI) Director Sells $1,939,261.20 in Stock” was reported by Ticker Report and is the property of of Ticker Report. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3289350/icu-medical-icui-director-sells-1939261-20-in-stock.html.
ICU Medical Company Profile
ICU Medical, Inc develops, manufactures, and sells medical devices used in infusion therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein for use in hospitals and ambulatory clinics.
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.